2023 Fiscal Year Final Research Report
Development of a Novel Treatment for Non-Alcoholic Fatty Liver Disease Focusing on the Intestinal Barrier
| Project/Area Number |
21K07966
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 非アルコール性脂肪肝疾患 / 腸管バリア / フェカリバクテリウム |
|---|
| Outline of Final Research Achievements |
Fecalibacterium is decreased in stools in patients with non-alcoholic fatty liver and advanced fibrosis. Administration of Fecalibacterium to a mouse model of hepatocellular carcinoma inhibited the progression of hepatocellular carcinoma, and the mechanism was related to the intestinal barrier and CD8 T cells.
|
| Free Research Field |
消化器内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
NAFLD-HCC症例でフェカリバクテリウムを増やす治療や腸管バリア、CD8をターゲットとした新規治療開発が重要である。
|
